Table 3.

Treatment of multifocal motor neuropathy based on evidence of clinical trials.

Treatment	Trial	Year	Trial design	Patients (n)	Outcome
Effective treatment
IVIg	Léger et al.	2001	IVIg (500 mg/kg/day, 5d 1 x month for 3 months versus placebo, double-blind, randomized, controlled crossover trial	18	7/9 patients who received IVIg responded compared with 2/9 patients who received placebo (p¼0.03). No differences in MRC score, electrophysiological studies and changes in anti-GM1 antibody titers.
IVIg	Federico et al.	2000	IVIg (0.4 g/kg/day, 5d) versus placebo, double-blind, randomized, controlled crossover trial	16	Improvement in NDS with IVIg treatment compared to placebo (p¼ 0.038) after 28 d. Improvement in grip strength (p¼0.0021) and conduction block (p¼0.037) with IVIg treatment.
IVIg	Azulay et al.	1994	IVIg (0.4 g/kg/day, 5d) versus placebo, double-blind, randomized, controlled crossover trial	12	Improvement in muscle strength after IVIg treatment.
IVIg	Van den Bergh et al.	1997	IVIg (2 x 0.4g/kg/day, 5d) (n = 4) and placebo; IVIg (1 x 0.4g/kg/day, 5 d) and placebo (n¼2), double-blind, randomized, controlled crossover trial	6	Clinical improvement in 5/6 patients with IVIg but not placebo.
Presumably ineffective treatment
Combination of IVIg and mycophenolate mofetil	Pieper et al.	2007	Standard dose IVIg every 2–5 weeks+1000mg/d mycophenolate mofetil first week then 2000 mg/d versus placebo for 12 months, randomized, double-blind, placebo-controlled study	28	No statistical differences in primary endpoint (IVIg dose reduction of 50% during adjunctive treatment).

PE, plasma exchange; IVIg, intravenous immunoglobulins; NDS, neurological disability score; MIU, million international units, s.c., subcutaneously.